Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect and Safety of Semaglutide 7.2 mg Once-weekly in Participants With Obesity

NCT05646706 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT05646706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05646706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect and Safety of Semaglutide 7.2 mg Once-weekly in Participants With Obesity
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
January 4, 2023
Completion date
November 26, 2024
Enrollment
1,407 (actual)
Sites
107

Conditions

As the registry lists them; a condition with its own page is linked.

obesity